Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.
CANbridge Pharmaceuticals Inc. announced that all resolutions proposed at their Extraordinary General Meeting (EGM) held on December 4, 2025, were passed by shareholders. The resolutions included granting a new general mandate to the company’s directors to issue shares and extending this mandate to shares repurchased by the company. This approval reflects strong shareholder support and may enhance the company’s financial flexibility, potentially impacting its strategic initiatives and market positioning.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates primarily in the biotechnology sector, aiming to address unmet medical needs in these specialized markets.
Average Trading Volume: 3,407,664
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.13B
Learn more about 1228 stock on TipRanks’ Stock Analysis page.